Nexocyte™ tissue
therapeutics platform
Fluicell is transforming how we treat disease with one-of-a-kind tissue solutions for regenerative medicine and drug screening.
With the groundbreaking Nexocyte™ platform, based on twenty years of disruptive and patent-protected R&D, we are creating new ways to target serious diseases using precision-engineered biological tissues.
Our transplantable tissues have the potential to help patients living with uncurable tissue damage related to cardiac, pulmonary, metabolic, kidney and other diseases. Fluicell’s first ambitious goal is to develop transplantable tissues to cure type 1 diabetes, impacting the lives of millions of patients.
Nexocyte-generated tissues also enable our world-leading partners to advance their drug-screening capabilities for the development of game-changing medicines.
Platform
Learn more about Nexocyte, Fluicell’s universal tissue production platform, based on our high-resolution single-cell bioprinting technology Biopixlar.
pipeline
Our pipeline consists of products based on our tissue production platform, including tissue-based therapeutics for type 1 diabetes treatment, and cardiac toxicity and kidney disease screening models.
Partner with us!
Learn about what we hope to achieve in partnership with innovation-driven pharmaceutical companies. Have questions or interested in exploring a collaboration? Get in touch.